These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 37232422)

  • 1. Implementing a Surveillance-Based Approach to Create a Statewide Viral Clearance Cascade for Hepatitis C Among People With HIV and HCV Coinfection in Connecticut.
    Wegener M; Brooks R; Speers S; Nichols L; Villanueva M
    Public Health Rep; 2024; 139(2):208-217. PubMed ID: 37232422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterizing Persons With HIV/HCV Coinfection Who Remain Untreated for Hepatitis C at Four HIV Clinics in Connecticut (CT): Role of Multiple Overlapping Barriers at the Individual and Clinic System Levels.
    Zhao A; Wegener M; Brooks R; Mininberg L; Helou E; Maughan A; Villanueva M
    Health Promot Pract; 2023 Sep; 24(5):1029-1038. PubMed ID: 37439687
    [No Abstract]   [Full Text] [Related]  

  • 3. Creating a Longitudinal HCV Care Cascade for Persons With HIV/HCV Coinfection in Selected HIV Clinics Using Data to Care Methods.
    Brooks R; Wegener M; Speers S; Nichols L; Sideleau R; Valeriano T; Buchelli M; Villanueva M
    Health Promot Pract; 2023 Sep; 24(5):1039-1049. PubMed ID: 37439600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The hepatitis C cascade of care in HIV/hepatitis C virus coinfected individuals in Europe: regional and intra-regional differences.
    Fursa O; Mocroft A; Lazarus JV; Amele S; Lundgren J; Matulionyte R; Rasmussen LD; Rockstroh JK; Parczewski M; Jilich D; Moreno S; Vassilenko A; Lacombe K; Wandeler G; Borodulina E; Brännström J; Wiese L; Orkin C; Behrens GMN; Mansinho K; Portu JJ; Peters L;
    AIDS; 2022 Mar; 36(3):423-435. PubMed ID: 34690281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recently acquired hepatitis C virus infection among people living with human immunodeficiency virus at a university hospital in Taiwan.
    Huang MH; Sun HY; Ho SY; Chang SY; Hsieh SM; Sheng WH; Chuang YC; Huang YS; Su LH; Liu WC; Su YC; Hung CC
    World J Gastroenterol; 2021 Oct; 27(37):6277-6289. PubMed ID: 34712032
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Microelimination of Hepatitis C Among People With Human Immunodeficiency Virus Coinfection: Declining Incidence and Prevalence Accompanying a Multicenter Treatment Scale-up Trial.
    Doyle JS; van Santen DK; Iser D; Sasadeusz J; O'Reilly M; Harney B; Traeger MW; Roney J; Cutts JC; Bowring AL; Winter R; Medland N; Fairley CK; Moore R; Tee BK; Asselin J; El-Hayek C; Hoy JF; Matthews GV; Prins M; Stoové MA; Hellard ME
    Clin Infect Dis; 2021 Oct; 73(7):e2164-e2172. PubMed ID: 33010149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gaps in hepatitis C virus prevention and care for HIV-hepatitis C virus co-infected people who inject drugs in Canada.
    Lanièce Delaunay C; Maheu-Giroux M; Marathe G; Saeed S; Martel-Laferrière V; Cooper CL; Walmsley S; Cox J; Wong A; Klein MB;
    Int J Drug Policy; 2022 May; 103():103627. PubMed ID: 35218989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The rate of hepatitis C reinfection in Canadians coinfected with HIV and its implications for national elimination.
    Young J; Wang S; Lanièce Delaunay C; Cooper CL; Cox J; Gill MJ; Hull M; Walmsley S; Wong A; Klein MB;
    Int J Drug Policy; 2023 Apr; 114():103981. PubMed ID: 36893502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Direct-acting antiviral treatment against hepatitis C virus infection in HIV-Infected patients - "En route for eradication"?
    Pradat P; Pugliese P; Poizot-Martin I; Valantin MA; Cuzin L; Reynes J; Billaud E; Huleux T; Bani-Sadr F; Rey D; Frésard A; Jacomet C; Duvivier C; Cheret A; Hustache-Mathieu L; Hoen B; Cabié A; Cotte L;
    J Infect; 2017 Sep; 75(3):234-241. PubMed ID: 28579302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low hepatitis C virus reinfection rate despite ongoing risk following universal access to direct-acting antiviral therapy among people living with HIV.
    Hosseini-Hooshyar S; Martinello M; Yee J; Read P; Baker D; Post JJ; Finlayson R; Bloch M; Doyle JS; Shaw D; Hellard M; Petoumenos K; Carson J; Dore GJ; Matthews GV;
    AIDS; 2020 Jul; 34(9):1347-1358. PubMed ID: 32590433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The British HIV Association national clinical audit 2021: Management of HIV and hepatitis C coinfection.
    Raya RP; Curtis H; Kulasegaram R; Cooke GS; Burns F; Chadwick D; Sabin CA;
    HIV Med; 2023 Apr; 24(4):471-479. PubMed ID: 36172948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis C Virus Elimination in the Human Immunodeficiency Virus-Coinfected Population: Leveraging the Existing Human Immunodeficiency Virus Infrastructure.
    Clement ME; Collins LF; Wilder JM; Mugavero M; Barker T; Naggie S
    Infect Dis Clin North Am; 2018 Jun; 32(2):407-423. PubMed ID: 29778263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DAA-mediated HCV cure reduces HIV DNA levels in HCV/HIV coinfected people.
    Gobran ST; Pagliuzza A; Khedr O; Fert A; Chomont N; Bruneau J; Klein MB; Ancuta P; Shoukry NH
    J Virol; 2023 Dec; 97(12):e0110523. PubMed ID: 38051044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiviral regimen complexity index as an independent predictor of sustained virologic response in patients with chronic hepatitis C.
    Galán RJ; Cidoncha EC; Martin MF; Rodriguez CC; Almeida CV; Verdugo RM
    J Manag Care Pharm; 2013; 19(6):448-53. PubMed ID: 23806058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Hepatitis C Virus Cure on Depressive Symptoms in the Human Immunodeficiency Virus-Hepatitis C Virus Coinfected Population in Canada.
    Marathe G; Moodie EEM; Brouillette MJ; Lanièce Delaunay C; Cox J; Martel-Laferrière V; Gill J; Cooper C; Pick N; Vachon ML; Walmsley S; Klein MB;
    Clin Infect Dis; 2023 Feb; 76(3):e702-e709. PubMed ID: 35789253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis C coinfection and extrahepatic cancer incidence among people living with HIV.
    Willis SJ; Kim HN; Achenbach CJ; Cachay ER; Christopoulos KA; Crane HM; Franco RA; Hurt CB; Kitahata MM; Moore RD; Silverberg MJ; Tien PC; Westreich D; Marcus JL
    HIV Med; 2022 Jul; 23(6):620-628. PubMed ID: 34951105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of direct-acting antiviral treatment on reducing mortality among Medicare beneficiaries with HIV and HCV coinfection.
    Yin X; Kong L; Du P; Jung J
    AIDS Care; 2022 Oct; 34(10):1330-1337. PubMed ID: 34581640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microelimination or Not? The Changing Epidemiology of Human Immunodeficiency Virus-Hepatitis C Virus Coinfection in France 2012-2018.
    Cotte L; Hocqueloux L; Lefebvre M; Pradat P; Bani-Sadr F; Huleux T; Poizot-Martin I; Pugliese P; Rey D; Cabié A;
    Clin Infect Dis; 2021 Nov; 73(9):e3266-e3274. PubMed ID: 33400777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trends in hepatitis C virus coinfection and its cascade of care among adults living with HIV in Asia between 2010 and 2020.
    Ross J; Rupasinghe D; Avihingsanon A; Lee MP; Pujari S; Sharp G; Kumarasamy N; Khusuwan S; Khol V; Agus Somia IK; Pham TN; Kiertiburanakul S; Choi JY; Duy Do C; Sohn AH; Jiamsakul A;
    PLoS One; 2023; 18(6):e0287909. PubMed ID: 37379314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis C virus micro-elimination within a clinic for people with HIV: challenges in the home stretch.
    Hanna J; Sufian J; Suh JS; Jimenez HR
    HIV Med; 2022 Aug; 23(7):801-806. PubMed ID: 35150183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.